The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.
Chief Executive Officer
“Today’s private placement demonstrates the strength of Sequana Medical and the appeal of our investment case, bringing our alfapump® platform to address clear unmet medical needs of liver disease and heart failure patients. The continued support of our existing investors, as well as new experienced life sciences investors and industry experts, is an endorsement of the strong progress we have made over the last year. The proceeds of the transaction will enable us to continue to progress towards launching alfapump® for the treatment of recurrent or refractory liver ascites in the U.S., which we expect in H1 2022, as well as driving forward the clinical development of alfapump® DSR as a potential chronic therapy for heart failure patients who are not well controlled on diuretics.”
JANUARY 22, 2020
Sequana Medical successfully raises EUR 19.0 million
JANUARY 22, 2020
Sequana Medical Launches Equity Placement
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.